Hidradenitis Suppurativa (HS)
48
17
18
16
Key Insights
Highlights
Success Rate
94% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
2.1%
1 terminated out of 48 trials
94.1%
+7.6% vs benchmark
23%
11 trials in Phase 3/4
38%
6 of 16 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 16 completed trials
Clinical Trials (48)
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
Nd:YAG vs Alexandrite Laser Treatment in Hidradenitis Suppurativa
Efficacy and Safety of SCT650C in Participants With Moderate to Severe Hidradenitis Suppurativa
A Single-center, Prospective, Self-controlled, Observational Real-world Study of the Efficacy and Safety of Anti-IL-17A/F Monoclonal Antibody Combined With Non-ablative Dot Laser for the Treatment of Mild to Moderate Hidradenitis Suppurativa
Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa
A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic
A Study With CIT-013 in HS Patients
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
Evaluating Legit.Health Plus Support for Improving Diagnosis of Generalized Pustular Psoriasis and Other Skin Conditions Among Primary Care Physicians and Dermatologists
Evaluating an Artificial Intelligence Tool to Help Primary Care Doctors Diagnose Skin Conditions.
Radiotherapy for Refractory Hidradenitis Suppurativa
Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense
The Safety and Efficacy of Roflumilast Foam in HS
A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa
MAIT Cells in Hidradenitis Suppurativa
A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa
A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradenitis Suppurativa (HS) Who Took Part in a Previous Study With Spesolimab
A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)
Real-World Study on the Burden of Hidradenitis Suppurativa